Neoadjuvant chemotherapy in urothelial bladder cancer

Impact of regimen and variant histology

Hristos Kaimakliotis, M. Francesca Monn, Jane S. Cho, Jose A. Pedrosa, Noah M. Hahn, Costantine Albany, Paul T. Gellhaus, K. Clinton Cary, Timothy Masterson, Richard Foster, Richard Bihrle, Liang Cheng, Michael Koch

Research output: Contribution to journalArticle

Abstract

Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.

Original languageEnglish (US)
Pages (from-to)1795-1804
Number of pages10
JournalFuture Oncology
Volume12
Issue number15
DOIs
StatePublished - Aug 1 2016

Fingerprint

Urinary Bladder Neoplasms
Histology
Drug Therapy
Cisplatin
Vinblastine
Methotrexate
Doxorubicin
Cystectomy
gemcitabine
Survival
Neoplasms

Keywords

  • bladder cancer
  • cystectomy
  • downstaging
  • neoadjuvant chemotherapy
  • pathologic response
  • variant histology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neoadjuvant chemotherapy in urothelial bladder cancer : Impact of regimen and variant histology. / Kaimakliotis, Hristos; Monn, M. Francesca; Cho, Jane S.; Pedrosa, Jose A.; Hahn, Noah M.; Albany, Costantine; Gellhaus, Paul T.; Cary, K. Clinton; Masterson, Timothy; Foster, Richard; Bihrle, Richard; Cheng, Liang; Koch, Michael.

In: Future Oncology, Vol. 12, No. 15, 01.08.2016, p. 1795-1804.

Research output: Contribution to journalArticle

@article{dced1cf0f9e840b28fd7e10fb3ca3f0c,
title = "Neoadjuvant chemotherapy in urothelial bladder cancer: Impact of regimen and variant histology",
abstract = "Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9{\%} of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.",
keywords = "bladder cancer, cystectomy, downstaging, neoadjuvant chemotherapy, pathologic response, variant histology",
author = "Hristos Kaimakliotis and Monn, {M. Francesca} and Cho, {Jane S.} and Pedrosa, {Jose A.} and Hahn, {Noah M.} and Costantine Albany and Gellhaus, {Paul T.} and Cary, {K. Clinton} and Timothy Masterson and Richard Foster and Richard Bihrle and Liang Cheng and Michael Koch",
year = "2016",
month = "8",
day = "1",
doi = "10.2217/fon-2016-0056",
language = "English (US)",
volume = "12",
pages = "1795--1804",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in urothelial bladder cancer

T2 - Impact of regimen and variant histology

AU - Kaimakliotis, Hristos

AU - Monn, M. Francesca

AU - Cho, Jane S.

AU - Pedrosa, Jose A.

AU - Hahn, Noah M.

AU - Albany, Costantine

AU - Gellhaus, Paul T.

AU - Cary, K. Clinton

AU - Masterson, Timothy

AU - Foster, Richard

AU - Bihrle, Richard

AU - Cheng, Liang

AU - Koch, Michael

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.

AB - Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.

KW - bladder cancer

KW - cystectomy

KW - downstaging

KW - neoadjuvant chemotherapy

KW - pathologic response

KW - variant histology

UR - http://www.scopus.com/inward/record.url?scp=84979735281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979735281&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0056

DO - 10.2217/fon-2016-0056

M3 - Article

VL - 12

SP - 1795

EP - 1804

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -